In August CTS begins source plasma testing as a new line of business to one of the largest plasma fractionators in the industry.
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....